Gilead Trial Pause Adds To Merck & Co’s HIV Concerns
Might Be End Of Partnership
Executive Summary
The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.
You may also be interested in...
Gilead’s Lenacapavir On The Move Again As FDA Lifts Clinical Hold
The long-acting HIV drug’s greatest potential is for pre-exposure prophylaxis, where it would compete against ViiV’s long-acting injectable Apretude.
GSK Looks To Long-Acting Therapy To Restore Lead In HIV
GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.
Safety Concerns Halt Merck & Co’s Once-Weekly HIV Combination
Merck & Co. is looking to compete in the burgeoning long-acting HIV market, but a safety halt to a Phase II trial could disrupt those plans.